Differential effects of d-sotalol, quinidine, and amiodarone on dispersion of ventricular repolarization in the isolated rabbit heart

Journal of Cardiovascular Electrophysiology

Volumn 8, Issue 11, 1997, Pages 1239-1245

  Zabel, Markus ^a,c   Hohnloser, Stefan H ^a   Behrens, Steffen ^a   Woosley, Raymond L ^b   Franz, Michael R ^b  

^a GEORGETOWN UNIVERSITY   (United States)

^b GOETHE UNIVERSITY   (Germany)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Action potential; Amiodarone; Antiarrhythmic drugs; d sotalol; Dispersion of repolarization; Quinidine

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; QUINIDINE; SOTALOL;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; HEART VENTRICLE; ISOLATED HEART; NONHUMAN; PRIORITY JOURNAL; RABBIT;

EID: 0030671179     PISSN: 10453873     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8167.1997.tb01014.x     Document Type: Article

References (31)

1. Han J, Moe GK: Nonuniform recovery of excitability in ventricular muscle. Circ Res 1964; 14:44-54.
2. Kuo CS, Munakata K, Reddy CP,et al: Characteristics and possible mechanism of ventricular arrhythmia dependent on the dispersion of action potential durations. Circulation 1983;67:1356-1367.
3. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321: 406-412.
4. Singh BN: Controlling cardiac arrhythmias: To delay conduction or to prolong refractoriness? Cardiovasc Drug Ther 1989;3:671-674.
5. Singh BN, Venkatesh N, Nademanee K,et al: The historical development, cellular electrophysiology and pharmacology of amiodarone. Prog Cardiovasc Dis 1989;31:249-280.
6. Hohnloser SH, Woosley RL: Sotalol. N Engl J Med 1994;331:31-38.
7. Surawicz B: Electrophysiologic substrate of torsade de pointes: Dispersion of repolarization or early afterdepolarizations? J Am Coll Cardiol 1989;14:172-184.
8. Hii JT, Wyse DG, Gillis AM,et al: Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class la antiarrhythmic drugs and amiodarone. Circulation 1992;86:1376-1382.
9. Hohnloser SH, Singh BN: Proarrhythmia with class antiarrhythmic drugs: Definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. J Cardiovasc Electrophysiol 1995;6: 920-936.
10. Waldo AL, Camm AJ, de Ruyter H, et al., for the SWORD Investigators: Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996;348:7-12.
11. Coplen SE, Antman EM, Berlin JA,et al: Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control-trial. Circulation 1990; 82:11061116.
12. Hohnloser SH, van de Loo A, Baedeker F: Efficacy and proarrhythmic hazards of pharmacologie cardioversion of atrial fibrillation: Prospective comparison of sotalol versus quinidine. J Am Coll Cardiol 1995;26:852-858.
13. Zabel M, Portnoy S, Franz MR: Electrocardiographic indexes of dispersion of ventricular repolarization: An isolated heart validation study. J Am Coll Cardiol 1995:25:746-752.
14. Franz MR, Chin MC, Sharkey HR,et al: A new single catheter technique for simultaneous measurement of action potential duration and refractory period in vivo. J Am Coll Cardiol 1990;16:878-886.
15. Franz MR, Kirchhof P, Fabritz CL,et al: Computer analysis of monophasic action potential recordings: Manual validation and clinically pertinent applications PACE 1995:18:1666-1678.
16. Venkatesh N, Somani P, Bersohn M,et al: Electropharmacology of amiodarone: Absence of relationship to serum, myocardial, and cardiac sarcolemmal membrane drug concentrations. Am Heart J 1986;112: 916-922.
17. Kato R, Venkatesh N, Kamiya K,et al: Electrophysiologic effects of desethylamiodarone, an active metabolite of amiodarone: Comparison with amiodarone during chronic administration in rabbits. Am Heart J 1988; 115:351-359.
18. Zabel M, Hohnloser SH, Behrens S,et al: Onset, characteristics, and mechanism of torsade de pointes: Insights from a new model in the isolated rabbit heart combining multiple tissue-level recordings with a si-multaneous electrocardiogram. (Abstract) Circulation 1996;94:I-736.
19. El-Sherif N, Bekheit SS, Henkin R: Quinidine-induced long QTU interval and torsade de pointes: Role of bradycardia-dependent early afterdepolarizations. J Am Coll Cardiol 1989;14:252-257.
20. Roden DM, Woosley RL, Primm RK: Incidence and clinical features of the quinidine-associated long QT syndrome: Implications for patient care. Am Heart J 1986;111:1088-1093.
21. Thompson KA, Murray JJ, Blair IA,et al: Plasma concentrations of quinidine, its major metabolites, and dihydroquinidine in patients with torsades de pointes. Clin Pharmacol Ther 1988;43:636-642.
22. Hohnloser SH, Klingenheben T, Singh BN: Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia. Ann Intern Med 1994;7:529-535.
23. Singh SN, Fletcher RD, Fischer SO,et al: Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995; 333:77-82.
24. Julian DG, Camm AJ, Frangin G,et al: Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997;349:667-674.
25. Cairns JA, Connolly Si, Roberts R,et al: Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet 1997:349:675-682.
26. Cui G, Sen L, Sager P,et al: Effects of amiodarone, sematilide, and sotalol on QT dispersion. Am J Cardiol 1994;74:896-900.
27. Wyse KR, Ye V, Campbell TJ: Action potential prolongation exhibits simple dose-dependence for sotalol, but reverse dose-dependence for quinidine and disopyramide: Implications for proarrhythmia due to triggered activity. J Cardiovasc Pharmacol 1993;21:316-322.
28. Berger F, Borchard U, Hafner D: Effects of (+)- and (+/-)-sotalol on repolarizing outward currents and pacemaker current in sheep cardiac Purkinje fibres. Naunyn Schmiedebergs Arch Pharmacol 1989;340: 696-704.
29. + channel currents by quinidine. Circ Res 1993;73:351-359.
30. +-Channels in Cardiovascular Medicine. Springer Verlag, Paris, 1993, pp. 247-272.
31. Lubic SP, Nguyen KP, Dave B,et al: Antiarrhythmic agent amiodarone possesses calcium channel blocker properties. J Cardiovasc Pharmacol 1994;24:707-714.